282 related articles for article (PubMed ID: 24059244)
1. Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control.
de Rinaldis E; Gazinska P; Mera A; Modrusan Z; Fedorowicz GM; Burford B; Gillett C; Marra P; Grigoriadis A; Dornan D; Holmberg L; Pinder S; Tutt A
BMC Genomics; 2013 Sep; 14():643. PubMed ID: 24059244
[TBL] [Abstract][Full Text] [Related]
2. Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.
Terkelsen T; Russo F; Gromov P; Haakensen VD; Brunak S; Gromova I; Krogh A; Papaleo E
Breast Cancer Res; 2020 Jun; 22(1):73. PubMed ID: 32605588
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR
J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940
[TBL] [Abstract][Full Text] [Related]
4. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.
Chang YY; Kuo WH; Hung JH; Lee CY; Lee YH; Chang YC; Lin WC; Shen CY; Huang CS; Hsieh FJ; Lai LC; Tsai MH; Chang KJ; Chuang EY
Mol Cancer; 2015 Feb; 14():36. PubMed ID: 25888956
[TBL] [Abstract][Full Text] [Related]
5. Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer.
Avery-Kiejda KA; Braye SG; Mathe A; Forbes JF; Scott RJ
BMC Cancer; 2014 Jan; 14():51. PubMed ID: 24479446
[TBL] [Abstract][Full Text] [Related]
6. Integrative analysis of breast cancer profiles in TCGA by TNBC subgrouping reveals novel microRNA-specific clusters, including miR-17-92a, distinguishing basal-like 1 and basal-like 2 TNBC subtypes.
Kalecky K; Modisette R; Pena S; Cho YR; Taube J
BMC Cancer; 2020 Feb; 20(1):141. PubMed ID: 32085745
[TBL] [Abstract][Full Text] [Related]
7. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
[TBL] [Abstract][Full Text] [Related]
8. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
[TBL] [Abstract][Full Text] [Related]
9. Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer.
Bottai G; Diao L; Baggerly KA; Paladini L; Győrffy B; Raschioni C; Pusztai L; Calin GA; Santarpia L
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106823
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of Smurf2, a tumor-suppressive ubiquitin ligase, in triple-negative breast cancers: involvement of the RB-microRNA axis.
Liu X; Gu X; Sun L; Flowers AB; Rademaker AW; Zhou Y; Kiyokawa H
BMC Cancer; 2014 Feb; 14():57. PubMed ID: 24485087
[TBL] [Abstract][Full Text] [Related]
11. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Riaz M; van Jaarsveld MT; Hollestelle A; Prager-van der Smissen WJ; Heine AA; Boersma AW; Liu J; Helmijr J; Ozturk B; Smid M; Wiemer EA; Foekens JA; Martens JW
Breast Cancer Res; 2013 Apr; 15(2):R33. PubMed ID: 23601657
[TBL] [Abstract][Full Text] [Related]
12. miRNA-135b Contributes to
Uva P; Cossu-Rocca P; Loi F; Pira G; Murgia L; Orrù S; Floris M; Muroni MR; Sanges F; Carru C; Angius A; De Miglio MR
Int J Med Sci; 2018; 15(6):536-548. PubMed ID: 29725243
[TBL] [Abstract][Full Text] [Related]
13. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
[TBL] [Abstract][Full Text] [Related]
14. The shaping and functional consequences of the microRNA landscape in breast cancer.
Dvinge H; Git A; Gräf S; Salmon-Divon M; Curtis C; Sottoriva A; Zhao Y; Hirst M; Armisen J; Miska EA; Chin SF; Provenzano E; Turashvili G; Green A; Ellis I; Aparicio S; Caldas C
Nature; 2013 May; 497(7449):378-82. PubMed ID: 23644459
[TBL] [Abstract][Full Text] [Related]
15. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
[TBL] [Abstract][Full Text] [Related]
16. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Analysis of Differentially Expressed Profiles of lncRNAs/mRNAs and miRNAs with Associated ceRNA Networks in Triple-Negative Breast Cancer.
Yang R; Xing L; Wang M; Chi H; Zhang L; Chen J
Cell Physiol Biochem; 2018; 50(2):473-488. PubMed ID: 30308479
[TBL] [Abstract][Full Text] [Related]
18. Identification of Novel Breast Cancer Subtype-Specific Biomarkers by Integrating Genomics Analysis of DNA Copy Number Aberrations and miRNA-mRNA Dual Expression Profiling.
Li D; Xia H; Li ZY; Hua L; Li L
Biomed Res Int; 2015; 2015():746970. PubMed ID: 25961039
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
Matamala N; Vargas MT; González-Cámpora R; Arias JI; Menéndez P; Andrés-León E; Yanowsky K; Llaneza-Folgueras A; Miñambres R; Martínez-Delgado B; Benítez J
Oncotarget; 2016 Apr; 7(15):20068-79. PubMed ID: 26933805
[TBL] [Abstract][Full Text] [Related]
20. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.
O'Brien K; Lowry MC; Corcoran C; Martinez VG; Daly M; Rani S; Gallagher WM; Radomski MW; MacLeod RA; O'Driscoll L
Oncotarget; 2015 Oct; 6(32):32774-89. PubMed ID: 26416415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]